WO2001082895A3 - Guaifenesin sustained release formulation and tablets - Google Patents

Guaifenesin sustained release formulation and tablets Download PDF

Info

Publication number
WO2001082895A3
WO2001082895A3 PCT/US2001/013379 US0113379W WO0182895A3 WO 2001082895 A3 WO2001082895 A3 WO 2001082895A3 US 0113379 W US0113379 W US 0113379W WO 0182895 A3 WO0182895 A3 WO 0182895A3
Authority
WO
WIPO (PCT)
Prior art keywords
guaifenesin
release formulation
formulation
sustained release
tablet
Prior art date
Application number
PCT/US2001/013379
Other languages
French (fr)
Other versions
WO2001082895A2 (en
Inventor
Ralph W Blume
Robert D Davis
Donald J Keyser
Original Assignee
Adams Lab Inc
Ralph W Blume
Robert D Davis
Donald J Keyser
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24233984&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2001082895(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AU2001255680A priority Critical patent/AU2001255680B2/en
Priority to DE60133538T priority patent/DE60133538T2/en
Priority to DK01928870T priority patent/DK1276467T3/en
Priority to EP01928870A priority patent/EP1276467B1/en
Priority to CA2405031A priority patent/CA2405031C/en
Priority to MXPA02010556A priority patent/MXPA02010556A/en
Priority to JP2001579770A priority patent/JP2003531849A/en
Application filed by Adams Lab Inc, Ralph W Blume, Robert D Davis, Donald J Keyser filed Critical Adams Lab Inc
Priority to IL15201201A priority patent/IL152012A0/en
Priority to NZ521959A priority patent/NZ521959A/en
Priority to AU5568001A priority patent/AU5568001A/en
Publication of WO2001082895A2 publication Critical patent/WO2001082895A2/en
Publication of WO2001082895A3 publication Critical patent/WO2001082895A3/en
Priority to IL152012A priority patent/IL152012A/en
Priority to HK03104991A priority patent/HK1052651A1/en
Priority to IL190742A priority patent/IL190742A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants

Abstract

The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic resin, in a ratio range of about one-to-one (1:1) to about six-to-one (6:1), more preferably a range of about three-to-two (3:2) to about four-to-one (4:1), and most preferably about two-to-one (2:1), by weight. This formulation capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject. The invention also relates to a modified release guaifenesin tablet which has two portion: the first portion comprises an immediate release formulation of guaifenesin and the second portion comprises a sustained release formulation of guaifenesin as described above. This two portion, or bi-layer, tablet has a maximum serum concentration equivalent to that of an immediate release guaifenesin tablet, and is capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject.
PCT/US2001/013379 2000-04-28 2001-04-26 Guaifenesin sustained release formulation and tablets WO2001082895A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
AU5568001A AU5568001A (en) 2000-04-28 2001-04-26 Guaifenesin sustained release formulation and tablets
JP2001579770A JP2003531849A (en) 2000-04-28 2001-04-26 Guaifenesin sustained-release preparations and tablets
DK01928870T DK1276467T3 (en) 2000-04-28 2001-04-26 Formulations and tablets for delayed release of guaifenesin
EP01928870A EP1276467B1 (en) 2000-04-28 2001-04-26 Guaifenesin sustained release formulation and tablets
IL15201201A IL152012A0 (en) 2000-04-28 2001-04-26 Guaifenesin sustained release formulation and tablets
MXPA02010556A MXPA02010556A (en) 2000-04-28 2001-04-26 Guaifenesin sustained release formulation and tablets.
DE60133538T DE60133538T2 (en) 2000-04-28 2001-04-26 FORMULATION AND TABLETS WITH GUAIFENESINE WITH DELAYED RELEASE
AU2001255680A AU2001255680B2 (en) 2000-04-28 2001-04-26 Guaifenesin sustained release formulation and tablets
CA2405031A CA2405031C (en) 2000-04-28 2001-04-26 Guaifenesin sustained release formulation and tablets
NZ521959A NZ521959A (en) 2000-04-28 2001-04-26 Guaifenesin sustained release formulation and tablets
IL152012A IL152012A (en) 2000-04-28 2002-09-30 Guaifenesin sustained release formulation and tablets
HK03104991A HK1052651A1 (en) 2000-04-28 2003-07-10 Guaifenesin sustained release formulation and tablets
IL190742A IL190742A0 (en) 2000-04-28 2008-04-09 Guaifenesin sustained release formulation and tablets

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/559,542 US6372252B1 (en) 2000-04-28 2000-04-28 Guaifenesin sustained release formulation and tablets
US09/559,542 2000-04-28

Publications (2)

Publication Number Publication Date
WO2001082895A2 WO2001082895A2 (en) 2001-11-08
WO2001082895A3 true WO2001082895A3 (en) 2002-05-23

Family

ID=24233984

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/013379 WO2001082895A2 (en) 2000-04-28 2001-04-26 Guaifenesin sustained release formulation and tablets

Country Status (17)

Country Link
US (1) US6372252B1 (en)
EP (2) EP1913937A1 (en)
JP (1) JP2003531849A (en)
AT (1) ATE391494T1 (en)
AU (2) AU2001255680B2 (en)
CA (1) CA2405031C (en)
CY (1) CY1108166T1 (en)
DE (1) DE60133538T2 (en)
DK (1) DK1276467T3 (en)
ES (1) ES2301537T3 (en)
HK (1) HK1052651A1 (en)
IL (3) IL152012A0 (en)
MX (1) MXPA02010556A (en)
NZ (1) NZ521959A (en)
PT (1) PT1276467E (en)
TW (2) TWI326602B (en)
WO (1) WO2001082895A2 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596298B2 (en) * 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
CA2328628A1 (en) * 1999-12-21 2001-06-21 Cecile J. Schoenheider Moldable compositions
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US20030012820A1 (en) * 2001-06-12 2003-01-16 Upadhyay Ajay Hasmukhlal Compressible guaifenesin compositions, method for making same and method for making compressed guaifenesin dosage forms therefrom
ATE404179T1 (en) * 2001-09-28 2008-08-15 Mcneil Ppc Inc DOSAGE FORMS WITH CORE AND OUTER SHELL
JP2005528383A (en) * 2002-04-10 2005-09-22 ミラー，フレッド，エイチ． Multiphase, multiple compartment capsule system
EA007156B1 (en) * 2002-04-15 2006-08-25 Адамс Лэборетриз, Инк. Sustained release of guaifenesin combination drugs
PA8578501A1 (en) 2002-07-25 2005-02-04 Pharmacia Corp DOSAGE FORM ONCE A DAY OF PRAMIPEXOL
US7807197B2 (en) * 2002-09-28 2010-10-05 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
US20050152967A1 (en) * 2003-03-28 2005-07-14 Pfab, Lp Dynamic variable release
CA2524300C (en) * 2003-08-08 2008-10-28 Biovail Laboratories International Srl Modified-release tablet of bupropion hydrochloride
US20050131028A1 (en) * 2003-09-11 2005-06-16 Pharmacia Corporation Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
US20050096311A1 (en) * 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
US20050232986A1 (en) * 2003-12-17 2005-10-20 David Brown Dosage form containing promethazine and another drug
US9592197B2 (en) * 2004-12-16 2017-03-14 Sovereign Pharmaceuticals, Llc Dosage form containing diphenhydramine and another drug
US20070003622A1 (en) * 2004-12-16 2007-01-04 Sovereign Pharmaceuticals, Ltd. Diphenhydramine containing dosage form
PT1789021E (en) * 2004-08-13 2011-12-22 Boehringer Ingelheim Int Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
WO2006070406A1 (en) * 2004-12-29 2006-07-06 J.B. Chemicals & Pharmaceuticals Ltd Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof
US8673352B2 (en) * 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
US20060257473A1 (en) * 2005-05-11 2006-11-16 Porranee Puranajoti Extended release tablet
US20070141147A1 (en) * 2005-12-21 2007-06-21 Auriga Laboratories, Inc. Sequential release pharmaceutical formulations
US20080064694A1 (en) * 2006-09-11 2008-03-13 Auriga Laboratories, Inc. Multi-Phase Release Methscopolamine Compositions
WO2008033155A1 (en) * 2006-09-15 2008-03-20 Auriga Laboratories, Inc. Kits for prevention and treatment of rhinitis
US20080085312A1 (en) * 2006-10-04 2008-04-10 Auriga Laboratories, Inc. Multi-Phase Release Potassium Guaiacolsulfonate Compositions
JP5783725B2 (en) 2007-12-28 2015-09-24 インパックス ラボラトリーズ、 インコーポレイテッドＩｍｐａｘ Ｌａｂｏｒａｔｏｒｉｅｓ， Ｉｎｃ． Levodopa controlled release formulation and use thereof
US20090202633A1 (en) * 2008-01-03 2009-08-13 Siva Ramakrishna Velaga Extended release formulations of guaifenesin
TWI541246B (en) 2008-12-08 2016-07-11 歐陸斯迪公司 Dihydroetorphine
US20110065744A1 (en) * 2009-09-12 2011-03-17 Reckitt Benckiser Inc. Method Of Inhibiting Mucin Secretion
US9339478B2 (en) 2011-02-04 2016-05-17 Reckitt Benckiser Llc Pharmaceutical formulation
JP2011140510A (en) * 2011-03-17 2011-07-21 Biovail Lab Inc Modified-release tablet of bupropion hydrochloride
US20130172381A1 (en) 2012-01-03 2013-07-04 Chandrashekar Giliyar Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
ES2823000T3 (en) 2013-10-07 2021-05-05 Impax Laboratories Llc Muco-adhesive controlled release formulations of levodopa and / or levodopa esters and uses thereof
JP6184903B2 (en) * 2014-06-04 2017-08-23 ヴァレアント インターナショナル バミューダＶａｌｅａｎｔ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｂｅｒｍｕｄａ Bupropion hydrochloride modified release tablets
TWI535784B (en) 2014-08-26 2016-06-01 財團法人工業技術研究院 Shear thickening formulation and composite material employing the same
CA3001337C (en) 2015-10-09 2023-12-12 Reckitt Benckiser Llc Pharmaceutical formulation
CN105832671A (en) * 2016-04-13 2016-08-10 中国药科大学 Dry suspension for controlled-release of medicine and preparation method of dry suspension
US20220133647A1 (en) * 2019-03-01 2022-05-05 Avadel Legacy Pharmaceuticals, Llc Liquid guaifenesin compositions with stable extended release profiles

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0384514A2 (en) * 1989-02-21 1990-08-29 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
WO1998022097A2 (en) * 1996-11-20 1998-05-28 Bio Advances, Llc Controlled release matrix composition using polar polymer or monomer and poly(acrylic acid) blend
EP0875245A2 (en) * 1997-04-28 1998-11-04 Hercules Incorporated Substained release polymer blend matrix for pharmaceutical application

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065143A (en) 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
DE1467781A1 (en) 1963-07-15 1968-12-05 Boehringer Sohn Ingelheim Process for the production of coated tablets with extended release of active ingredients
US3362880A (en) 1963-09-20 1968-01-09 Dow Chemical Co Compressed drug tablets of ethyl cellulose, glyceryl monostearate, karaya gum, tragacanth, talc, and magnesium stearate
US3555151A (en) 1966-12-21 1971-01-12 Richardson Merrell Inc Long acting solid antacid
US3981984A (en) 1968-04-01 1976-09-21 Colorcon Incorporated Color film coating of tablets and the like
US3870790A (en) 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US4167558A (en) 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
US4140755A (en) 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4122157A (en) 1977-03-04 1978-10-24 Richardson-Merrell Inc. Nitrofurantoin sustained release tablet
US4357469A (en) 1979-06-14 1982-11-02 Forest Laboratories, Inc. Carrier base material for prolonged release therapeutic compositions
US4226849A (en) 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
US4543370A (en) 1979-11-29 1985-09-24 Colorcon, Inc. Dry edible film coating composition, method and coating form
US4259314A (en) 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4424235A (en) 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
US4369172A (en) 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4680323A (en) * 1983-12-01 1987-07-14 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
US4540566A (en) 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose
US4695464A (en) 1984-10-09 1987-09-22 The Dow Chemical Company Sustained release dosage form based on highly plasticized cellulose ether gels
US4851392A (en) 1985-02-05 1989-07-25 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
JPS61286330A (en) * 1985-06-11 1986-12-16 Teijin Ltd Slow-releasing medicinal preparation for oral administration
EP0227814A1 (en) 1985-07-02 1987-07-08 The Upjohn Company Therapeutic formulations with bimodal release characteristics
US4704285A (en) 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
US4699779A (en) 1986-02-18 1987-10-13 Victor Palinczar Waterproof sunscreen compositions
IT1191674B (en) 1986-03-07 1988-03-23 Eurand Spa FORMULATIONS FOR THE PREPARATION OF PROLONGED-RELEASE DRUGS SUITABLE FOR ORAL ADMINISTRATION
US4756911A (en) * 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
US4798725A (en) 1986-06-16 1989-01-17 Norwich Eaton Pharmaceuticals, Inc. Sustained release capsule
CH668553A5 (en) 1987-02-02 1989-01-13 Mepha Ag MEDICINAL PRODUCTS WITH DELAYED RELEASE OF THE ACTIVE SUBSTANCE.
NZ223619A (en) * 1987-02-27 1990-10-26 Lilly Co Eli Sustained release tablet containing cefaclor, a hydrophilic polymer and an acrylic polymer
US4968508A (en) 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US4786503A (en) 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US5200193A (en) 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
US4994276A (en) 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
JPH01153626A (en) * 1987-12-10 1989-06-15 Nippon Soda Co Ltd Sustained release spherical particle preparation
US4983398A (en) 1987-12-21 1991-01-08 Forest Laboratories, Inc. Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
CA2020895C (en) 1989-07-18 2004-02-17 Jean-Pierre Sachetto Polymer base blend compositions containing destructurized starch
IT1249443B (en) 1990-08-30 1995-02-23 Warner Lambert Co COMPOSITION INCLUDING A HYDROPHILE POLYMER AND A DIFFERENT HYDROPHILE MATERIAL.
US5098715A (en) 1990-12-20 1992-03-24 Burroughs Wellcome Co. Flavored film-coated tablet
US5403593A (en) 1991-03-04 1995-04-04 Sandoz Ltd. Melt granulated compositions for preparing sustained release dosage forms
US5164398A (en) 1991-04-01 1992-11-17 Merck & Co., Inc. Ibuprofen-antitussive combinations
US5208037A (en) 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
IT1250421B (en) 1991-05-30 1995-04-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION WITH BIO-ADHESIVE PROPERTIES.
US5292534A (en) 1992-03-25 1994-03-08 Valentine Enterprises, Inc. Sustained release composition and method utilizing xanthan gum and an active ingredient
US5656296A (en) * 1992-04-29 1997-08-12 Warner-Lambert Company Dual control sustained release drug delivery systems and methods for preparing same
DE69332801T2 (en) * 1992-11-30 2004-01-29 Kv Pharm Co TASTE-MASKED PHARMACEUTICAL SUBSTANCES
JPH06316517A (en) * 1993-02-22 1994-11-15 Grelan Pharmaceut Co Ltd Sustained-release preparation
IT1264517B1 (en) 1993-05-31 1996-09-24 Ekita Investments Nv PHARMACEUTICAL TABLET SUITABLE FOR THE RELEASE IN SUBSEQUENT TIMES OF THE ACTIVE PRINCIPLES CARRIED THEREIN
US5662933A (en) 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5451409A (en) 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
US5395626A (en) 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
IT1282650B1 (en) 1996-02-19 1998-03-31 Jagotec Ag PHARMACEUTICAL TABLET, CHARACTERIZED BY A HIGH INCREASE IN VOLUME IN CONTACT WITH BIOLOGICAL LIQUIDS
JPH1017497A (en) * 1996-07-02 1998-01-20 Takeda Chem Ind Ltd Sustained release pharmaceutical preparation and its production
US5807580A (en) 1996-10-30 1998-09-15 Mcneil-Ppc, Inc. Film coated tablet compositions having enhanced disintegration characteristics
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
FR2772615B1 (en) * 1997-12-23 2002-06-14 Lipha MULTILAYER TABLET FOR INSTANT RELEASE THEN PROLONGED ACTIVE SUBSTANCES
US5968554A (en) 1998-07-07 1999-10-19 Cascade Development, Inc. A Subsidiary Of Cardinal Health, Inc. Sustained release pharmaceutical preparation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0384514A2 (en) * 1989-02-21 1990-08-29 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
WO1998022097A2 (en) * 1996-11-20 1998-05-28 Bio Advances, Llc Controlled release matrix composition using polar polymer or monomer and poly(acrylic acid) blend
EP0875245A2 (en) * 1997-04-28 1998-11-04 Hercules Incorporated Substained release polymer blend matrix for pharmaceutical application

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BODMEIER, R. ET AL: "Prolonged release multiple-unit dosage forms based on water-soluble cellulosic polymers or aqueous latexes", PROC. PROGRAM INT. SYMP. CONTROLLED RELEASE BIOACT. MATER., 18TH (1991), 157-8. EDITOR(S): KELLAWAY, IAN W. PUBLISHER: CONTROLLED RELEASE SOC., DEERFIELD, ILL., XP001041674 *

Also Published As

Publication number Publication date
IL190742A0 (en) 2008-11-03
CA2405031C (en) 2011-12-06
DE60133538T2 (en) 2009-07-09
DK1276467T3 (en) 2008-08-04
ATE391494T1 (en) 2008-04-15
DE60133538D1 (en) 2008-05-21
HK1052651A1 (en) 2003-09-26
ES2301537T3 (en) 2008-07-01
JP2003531849A (en) 2003-10-28
MXPA02010556A (en) 2003-10-14
NZ521959A (en) 2004-10-29
CA2405031A1 (en) 2001-11-08
EP1276467B1 (en) 2008-04-09
CY1108166T1 (en) 2014-02-12
WO2001082895A2 (en) 2001-11-08
IL152012A0 (en) 2003-04-10
EP1913937A1 (en) 2008-04-23
TWI326602B (en) 2010-07-01
US6372252B1 (en) 2002-04-16
AU5568001A (en) 2001-11-12
IL152012A (en) 2010-04-15
PT1276467E (en) 2008-05-15
EP1276467A2 (en) 2003-01-22
AU2001255680B2 (en) 2006-02-16
TW200727919A (en) 2007-08-01
TWI314866B (en) 2009-09-21

Similar Documents

Publication Publication Date Title
WO2001082895A3 (en) Guaifenesin sustained release formulation and tablets
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
Sletten et al. Cytotoxic effects of extracts of compomers
WO2003103637A3 (en) Modified release, multiple unit drug delivery systems
EP2322146A3 (en) Microcapsule formulations comprising two pharmaceutically active ingredients
EP1287822A3 (en) Mesalazine controlled release oral pharmaceutical compositions
WO1998009597A3 (en) Cushioning beads and tablet comprising the same capable of forming a suspension
GEP20074022B (en) Pharmaceutical formulations comprising oxycodone and naloxone
WO2004010998A8 (en) Sustained-release tablet comprising reboxetine
ATE355829T1 (en) SOLID PHARMACEUTICAL COMPOSITION CONTAINING A LIPOPHILIC ACTIVE INGREDIENT AND THE PRODUCTION THEREOF
WO2007071581A3 (en) Pharmaceutical formulation for producing rapidly disintegrating tablets
UA42062C2 (en) Three-phase pharmaceutical form with constant and sustained release of amorphous active ingredient and methods for its manufacture
AU2003274681A1 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
MY127797A (en) 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol-containing pharmaceutical composition with slow release of active indgredient
FI20011852A (en) A process for the preparation of a dispersible tablet containing fluoxetine or an acid addition salt thereof
DE60326709D1 (en) PHARMACEUTICAL FORMULATIONS WITH IMPROVED BIOAVAILABILITY
Cartagena et al. New denture adhesive containing miconazole nitrate polymeric microparticles: Antifungal, adhesive force and toxicity properties
CA2566931A1 (en) Tablets exhibiting reduced drug release variability
WO2007017331A3 (en) Immediate release therapeutic systems for improved oral absorption of 7- [ (e) -tert-butyloxyiminomethyl] camptothecin
MY130332A (en) Pharmaceutical formulation comprising iota-carrageenan and at least one neutral gelling polymer
EA200401369A1 (en) SLOWLY RELAXING MEDICINAL COMPOSITIONS OF GUIPHENESINE
DE60320661D1 (en) SYSTEM WITH CONTROLLED RELEASE OF BIOACTIVE ACTIVE SUBSTANCES
HUP0500097A2 (en) Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
MXPA03008420A (en) Solid orally-dispersible pharmaceutical formulation.
MY137516A (en) Pharmaceutical composition comprising lumiracoxib

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001255680

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 152012

Country of ref document: IL

Ref document number: 2405031

Country of ref document: CA

Ref document number: IN/PCT/2002/1238/KOL

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 521959

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001928870

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2001 579770

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/010556

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 2001928870

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 521959

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 521959

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 190742

Country of ref document: IL